Topical formulations of PDE-4 inhibitors and their methods of use
US10206925B2 · kind B2 · utility
0Cited by
2References
40Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 7, 2017 |
| Grant date | Feb 19, 2019 |
| Priority date | — |
| Expiry date | Jun 7, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Embodiments herein are directed to topical formulations of a compound represented by the formula (I), salt, metabolite, prodrug, or hydrate thereof along with a solvent, and a base. The compound is a PDE4 inhibitor and the topical formulations may be used to treat dermatological conditions such as, but not limited to, atopic dermatitis, seborrheic dermatitis, alopecia, contact dermatitis, psoriasis, urticaria, eczema, burns, sunburn, pancreatitis, hepatitis, lichen planus, scleritis, scleroderma, dermatomyositis, itching associated with any of the preceding conditions or a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.